Abstracts Archive - Page 166 of 2425 - ACR Meeting Abstracts

Abstract Number: 0930 • ACR Convergence 2024
The Common Form of the Inflammatory Skin Disease Hidradenitis Suppurativa Is Associated with Low Nicastrin Expression in Dermal Fibroblasts
Kaitlin Williams, Beita Badiei, Hana Minsky and Luis Garza, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition characterized by painful nodules and abscesses in intertriginous areas. Despite its increasing prevalence, the etiology…
Abstract Number: 0927 • ACR Convergence 2024
Synovial Macrophage Heterogeneity and Dynamics in Steady Stateand Rheumatoid Arthritis Mouse Model Time Course
Jessica Maciuch¹, Yidan Wang², Tyler Therron³, Harris Perlman¹ and Deborah Winter⁴, ¹Northwestern University, Chicago, IL, ²Northwestern University, Hanover Park, IL, ³Northwestern University, Chicago, ⁴Northwestern University, Skokie, IL
Background/Purpose: Macrophages are vital contributors to both pro-inflammatory signaling and tissue repair processes involved in the pathogenesis and remission of Rheumatoid Arthritis (RA). Recent research…
Abstract Number: 0868 • ACR Convergence 2024
Autoantibodies to Joint-related Proteins Predict Severe Joint Destruction in Difficult-to-treat Rheumatoid Arthritis Patients
Inger Gjertsson¹, Monica Leu Agelii², Outi Sareila³, Erik Lönnblom⁴, Lennart TH Jacobsson⁵, Lei Cheng⁴, Kristina Forslind⁶, Ingiäld Hafström⁷, Maria Andersson⁸ and Rikard Holmdahl⁹, ¹University of Gothenburg, Gothenburg, Sweden, ²Institutionen för medicin, avd för reumatologi och inflammationsforskning, Goteborg, Sweden, ³Karolinska Institutet, Stockholm, Sweden, ⁴Karolinska Institute, Stockholm, Sweden, ⁵Lund University, Malmö, Sweden, ⁶Lund University, Department of Clinical Sciences Lund, Section of Rheumatology, Lund, Sweden, ⁷Karolinska Institutet, Department of Medicine Huddinge, Division of Gastroenterology and Rheumatology, and Karolinska University Hospital, Stockholm, Sweden, ⁸FoU Spenshult, Halmstad, Sweden, ⁹Department of Rheumatology and Inflammation Research, Institute for Medicine, Sahlgrenska Academy, University of Gothenburg, Stockholm, Stockholms Lan, Sweden
Background/Purpose: Although treatment of rheumatoid arthritis (RA) has improved there is still a significant number of patients who never reach low disease activity, known as…
Abstract Number: 0911 • ACR Convergence 2024
Activating B Cells Facilitates the Discovery of Latent Disease-associated Variants
David Murphy, Yao Fu, Jennifer Kelly, Richard Pelikan, Graham Wiley and Patrick Gaffney, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Although millions of disease-associated variants have been discovered using GWAS, most of these occur in non-coding regions and their mechanistic link to disease is…
Abstract Number: 0932 • ACR Convergence 2024
IRAK4 Degrader GS-6791 Inhibits TLR and IL-1R-Driven Inflammatory Signaling, and Ameliorates Disease in a Preclinical Arthritis Model
Grace Teng¹, Thomas Fung², Annamaria Mocciaro², Ceyda Llapashtica¹, Angie Hammond³, Jesse Gurgel⁴, zhiyu Huang¹, Maria Mouchess¹, Vanessa Gorney⁵, Wesley Minto¹, Sunish Mohanan¹, Adam Schrier¹, Wylie Palmer², Alexandra Borodovsky² and Gundula Min-oo¹, ¹Gilead Sciences, Foster City, CA, ²Nurix Therapeutics, San Francisco, CA, ³Gilead Sciences, Inc., Seattle, WA, ⁴Gilead Sciences, Seattle, CA, ⁵Alterome Therapeutics, San Diego, CA
Background/Purpose: Despite advances in treatment, chronic inflammatory diseases such as rheumatoid arthritis (RA) represent areas of high unmet medical need. IRAK4 is a proximal mediator…
Abstract Number: 0823 • ACR Convergence 2024
A Randomized, Double-Blind, Placebo-Controlled Trial of Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis with Polyangiitis
Carol Langford¹, Nader Khalidi², Jason Springer³, Marcia Friedman⁴, Bernhard Hellmich⁵, Christian Pagnoux⁶, Natasha Dehghan⁷, Ora Singer⁸, Curry Koening⁹, Yih Chang Lin¹⁰, Paul Monach¹¹, Larry Moreland¹², Aurore Fifi-Mah¹³, Oliver Flossmann¹⁴, Lindsy Forbess¹⁵, Peter Lanyon¹⁶, Eamonn Molloy¹⁷, Ulrich Specks¹⁸, Robert Spiera¹⁹, Elaine Yacyshyn²⁰, Carol McAlear²¹, Cristina Burroughs¹⁰, Rachel Jones²², Rennie Rhee²¹, Rula A. Hajj-Ali²³, Kenneth Warrington¹⁸, David Cuthbertson¹⁰, Jeffrey Krischer¹⁰, David Jayne²² and Peter Merkel²¹, and the Vasculitis Clinical Research Consortium and the European Vasculitis Society, ¹Cleveland Clinic, Moreland Hills, OH, ²McMaster University, Hamilton, ON, Canada, ³Vanderbilt University Medical Center, Franklin, TN, ⁴Oregon Health and Science University, Portland, OR, ⁵Medius Kliniken, Kirchheim unter Teck, Germany, ⁶Mount Sinai Hospital, Toronto, ON, Canada, ⁷University of British Columbia - Vancouver, Vancouver, BC, Canada, ⁸University of Michigan, Huntington Woods, MI, ⁹University of Texas Dell Medical School, Austin, TX, ¹⁰University of South Florida, Tampa, FL, ¹¹VA Boston Healthcare System, Boston, MA, ¹²University of Colorado, Denver, CO, ¹³University of Calgary, Calgary, AB, Canada, ¹⁴Royal Berkshire Hospital, Reading, United Kingdom, ¹⁵Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁶University of Nottingham, Nottingham, United Kingdom, ¹⁷St Vincent's University Hospital, Dublin, Ireland, ¹⁸Mayo Clinic, Rochester, MN, ¹⁹Scleroderma, Vasculitis, and Myositis Center, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, ²⁰University of Alberta, Edmonton, AB, Canada, ²¹University of Pennsylvania, Philadelphia, PA, ²²University of Cambridge, Cambridge, United Kingdom, ²³Cleveland Clinic, Cleveland, OH
Background/Purpose: Granulomatosis with polyangiitis (GPA) is a small-vessel vasculitis associated with frequent relapses. Following encouraging results from an open-label study, a randomized, double-blind, placebo-controlled trial…
Abstract Number: 0937 • ACR Convergence 2024
A Novel Quantitative Method Reveals Bone-Structural Changes During Course of Inflammatory Arthritis
Anders Nguyen¹, David McBride², Miriam Bollmann¹, Agnieszka Lastowska³ and Mattias Svensson⁴, ¹University of Gothenburg, Göteborg, Sweden, ²Calibr-Skaggs Institute for Innovative Medicines, La Jolla, CA, ³University of Gothenburg, Goteborg, Sweden, ⁴University of Gothenburg, Gothenburg, Sweden
Background/Purpose: Rheumatoid Arthritis (RA) is a chronic inflammatory disease characterized by both localized and generalized bone loss. The inhibition of Receptor Activator of Nuclear Factor…
Abstract Number: 0926 • ACR Convergence 2024
Macrophages and Nociceptor Neurons Form a Sentinel Unit Around Fenestrated Capillaries to Defend the Synovium from Systemic Challenges
Tetsuo Hasegawa and Menna Clatworthy, University of Cambridge, Cambridge, United Kingdom
Background/Purpose: A wide variety of systemic pathologies, including infectious and autoimmune diseases, are accompanied by joint pain or inflammation, often mediated by circulating immune complexes…
Abstract Number: 0956 • ACR Convergence 2024
Secreted Frizzled-Related Protein 2 (sFRP2) Regulates Wnt Signaling to Affect Mesenchymal Transition of Lung Epithelial Cells Participates in Interstitial Lung Disease
Yinlan Wu¹, Yanhong Li² and Yi Liu³, ¹West China Hospital of Sichuan University, Chengdu, Sichuan, China, ²West China School of Medicine and West China Hospital, Sichuan University, Cheng Du, Sichuan, China, ³West China Hospital, Sichuan University, Chengdu, China (People's Republic)
Background/Purpose: Investigation of Transcriptional Changes in Interstitial Lung Disease (ILD) and Exploration of Functional Effects of Differential Genes and Expressed Proteins in the Development of…
Abstract Number: 0957 • ACR Convergence 2024
Increased Collagen Deposition and Altered Immune Cell Profiles Are Present in Early and Late Stage Systemic Sclerosis with Gastrointestinal Involvement
Laura Much¹, Elena Pachera², Andrea Laimbacher¹, Henriette Didriksen³, Lars Aabakken⁴, Knut Ea Lundin⁴, Lumeng Li¹, Astrid Hofman¹, Pietro Bearzi⁵, Sophie Wagner⁶, Michael Scharl⁷, Øyvind Molberg⁸, Håvard Fretheim⁹, Oliver Distler¹⁰ and Anna-Maria Hoffmann-Vold⁹, ¹Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ²University Hospital Zurich, Zurich, Switzerland, ³Oslo University Hospital, Moss, Norway, ⁴Department of Transplantation Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway, ⁵Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Schlieren, Switzerland, ⁶University of Zurich, Schlieren, Switzerland, ⁷Department of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁸Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, ⁹Oslo University Hospital, Oslo, Norway, ¹⁰Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland
Background/Purpose: Gastrointestinal tract (GIT) involvement is highly prevalent among patients with systemic sclerosis (SSc) and is associated with high morbidity and mortality. However, treatment options…
Abstract Number: 0933 • ACR Convergence 2024
NLRP3 Inflammasome Promotes Release of Peptidyl Arginine Deiminases2 and 4 from Human Neutrophils
Teneema Kuriakose, Mingxin Yang, Lacie Scaletta and Gary Sims, Immunology Biosciences, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD
Background/Purpose: Autoantibodies targeting citrullinated proteins (ACPAs) are a characteristic feature and a diagnostic marker in rheumatoid arthritis (RA). The generation of citrullinated protein autoantigens is…
Abstract Number: 0875 • ACR Convergence 2024
Targeted IL-15 Muteins Provide Selective Expansion of KIR+ CD8 Regulatory T Cells, with the Potential to Ameliorate Disease in Autoimmune Patients with Deficient CD8 Treg Populations
Daniel Patton, Alex Chen, Justin Bowser, Kaelen Encarnacion, Jennifer Gardell, Emily Gilbertson, Susan Julien, Meghan Maurer, Brent Meengs, Nadine Morgan, Allison O'Rourke, Cong Tan, Jon Therriault, Kristine Swiderek and Courtney Crane, Mozart Therapeutics, Seattle, WA
Background/Purpose: CD8 Treg, characterized in human peripheral blood mononuclear cells (PBMC) by expression of inhibitory killer immunoglobulin receptors (KIRs), regulate immune balance by eliminating self-reactive…
Abstract Number: 0936 • ACR Convergence 2024
Schnurri-3 Inhibition Protects from NF-kB-induced Bone Loss in Inflammatory Arthritis
Priyanka Kushwaha¹, Catherine Manning², Tadatoshi Sato³, Yeon-Suk Yang³, Jae-Hyuck Shim⁴ and Ellen Gravallese⁵, ¹Department of Medicine/Division of Rheumatology, Inflammation and Immunity, Brigham and Women’s Hospital, Boston, MA, ²Brigham and Women's Hospital, Dedham, MA, ³Department of Medicine/Division of Rheumatology, Horae Gene Therapy Center, University of Massachusetts Chan Medical School, Worcester, MA, ⁴University of Massachusetts, Worcester, MA, ⁵Brigham and Women's Hospital, Harvard Medical School, Chestnut Hill, MA
Background/Purpose: In rheumatoid arthritis (RA), production of TNF promotes osteoclast activity and inhibits osteoblasts (OBs) and bone healing. Schnurri-3 (SHN3) is a potent suppressor of…
Abstract Number: 0827 • ACR Convergence 2024
Oral Corticosteroid-Sparing Effects of Mepolizumab in Eosinophilic Granulomatosis with Polyangiitis (EGPA): Results up to 7.4 Years from the Long-Term Access Programme
Paneez Khoury¹, Jared Silver², Gerhard Wolff³, Robert Price⁴, Rejina Verghis⁵, Emmeline Igboekwe² and Michael E Wechsler⁶, ¹National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, ²US Medical Affairs-Respiratory, GSK, Durham, ³Clinical Development-Respiratory, GSK, Collegeville, ⁴Biostatistics, GSK, Stevenage, United Kingdom, ⁵Biostatistics, Development Respiratory, GSK, Brentford, United Kingdom, ⁶Department of Medicine, National Jewish Health, Denver, CO
Background/Purpose: EGPA is a severe, rare, relapsing/remitting inflammatory disease, in which chronic or high oral corticosteroid (OCS) doses lead to adverse effects, adding to disease…
Abstract Number: 0963 • ACR Convergence 2024
Stratification According to Autoantibody Status in Systemic Sclerosis Reveals Distinct Molecular Signatures
Bénédicte ROUVIERE¹, Christelle Le dantec², Eléonore Bettacchioli³, Lorenzo Beretta⁴, Céline Cao², Christophe Jamin², Jacques-Olivier Pers⁵, Nathan Foulquier², Martin Kerick⁶, Javier Martin⁶, Marta Alarcon-Riquelme⁷, Claire de Moreuil⁸, Divi Cornec³ and Sophie Hillion², and PRECISESADS Clinical Consortium, PRECISESADS Metabolomic Study Group, ¹CHRU de Brest, LBAI. UMR 1227, University of Brest, Brest, France, ²LBAI. UMR 1227, University of Brest, Brest, France, ³Service de Rhumatologie, CHU de Brest, Brest, France, ⁴Scleroderma Unit, Fondazione IRCCS Ca' Granda, University of Milan, Milan, Italy, ⁵University of Brest, Brest, France, ⁶Instituto de Parasitología y Biomedicina 'López-Neyra', CSIC, PTS Granada, Spain, Granada, Spain, ⁷Fundación Progreso y Salud, Andalusian Government, Granada, Spain, ⁸Service de médecine interne, CHU de Brest, Brest, France
Background/Purpose: Systemic sclerosis is a heterogeneous disease, complicating its management. Its complexity and the insufficiency of clinical manifestations alone to delineate homogeneous patient groups further…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].